These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

989 related articles for article (PubMed ID: 29205637)

  • 1. A field guide for cancer diagnostics using cell-free DNA: From principles to practice and clinical applications.
    Volckmar AL; Sültmann H; Riediger A; Fioretos T; Schirmacher P; Endris V; Stenzinger A; Dietz S
    Genes Chromosomes Cancer; 2018 Mar; 57(3):123-139. PubMed ID: 29205637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
    Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
    Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor DNA in liquid biopsy: Current diagnostic limitation.
    Liu SC
    World J Gastroenterol; 2024 Apr; 30(15):2175-2178. PubMed ID: 38681986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
    Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
    Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How liquid biopsies can change clinical practice in oncology.
    Siravegna G; Mussolin B; Venesio T; Marsoni S; Seoane J; Dive C; Papadopoulos N; Kopetz S; Corcoran RB; Siu LL; Bardelli A
    Ann Oncol; 2019 Oct; 30(10):1580-1590. PubMed ID: 31373349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
    Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
    Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA.
    Gale D; Lawson ARJ; Howarth K; Madi M; Durham B; Smalley S; Calaway J; Blais S; Jones G; Clark J; Dimitrov P; Pugh M; Woodhouse S; Epstein M; Fernandez-Gonzalez A; Whale AS; Huggett JF; Foy CA; Jones GM; Raveh-Amit H; Schmitt K; Devonshire A; Green E; Forshew T; Plagnol V; Rosenfeld N
    PLoS One; 2018; 13(3):e0194630. PubMed ID: 29547634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.
    Thierry AR
    Methods Mol Biol; 2016; 1392():1-16. PubMed ID: 26843041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics.
    Song P; Wu LR; Yan YH; Zhang JX; Chu T; Kwong LN; Patel AA; Zhang DY
    Nat Biomed Eng; 2022 Mar; 6(3):232-245. PubMed ID: 35102279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologists and liquid biopsies: to be or not to be?
    Hofman P; Popper HH
    Virchows Arch; 2016 Dec; 469(6):601-609. PubMed ID: 27553354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathology in real time.
    Ryška A
    Cancer Metastasis Rev; 2016 Mar; 35(1):129-40. PubMed ID: 26931654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment.
    Filipska M; Rosell R
    Mol Oncol; 2021 Jun; 15(6):1667-1682. PubMed ID: 33969622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technical Advances in Circulating Cell-Free DNA Detection and Analysis for Personalized Medicine in Patients' Care.
    Sorbini M; Carradori T; Togliatto GM; Vaisitti T; Deaglio S
    Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
    Alix-Panabières C; Pantel K
    Cancer Discov; 2016 May; 6(5):479-91. PubMed ID: 26969689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liquid biopsy for precision diagnostics and therapeutics.
    Anitha K; Posinasetty B; Naveen Kumari K; Chenchula S; Padmavathi R; Prakash S; Radhika C
    Clin Chim Acta; 2024 Feb; 554():117746. PubMed ID: 38151071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
    Paolillo C; Londin E; Fortina P
    Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.
    Gold B; Cankovic M; Furtado LV; Meier F; Gocke CD
    J Mol Diagn; 2015 May; 17(3):209-24. PubMed ID: 25908243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Liquid biopsy analysis using cell-free DNA (cfDNA): Opportunities and limitations].
    Dahl E; Kloten V
    Pathologe; 2015 Nov; 36(6):572-8. PubMed ID: 26395890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-free DNA analysis in current cancer clinical trials: a review.
    Cisneros-Villanueva M; Hidalgo-Pérez L; Rios-Romero M; Cedro-Tanda A; Ruiz-Villavicencio CA; Page K; Hastings R; Fernandez-Garcia D; Allsopp R; Fonseca-Montaño MA; Jimenez-Morales S; Padilla-Palma V; Shaw JA; Hidalgo-Miranda A
    Br J Cancer; 2022 Feb; 126(3):391-400. PubMed ID: 35027672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.